See every side of every news story
Get Started
SubscribeLogin
Israel-Hamas Conflict
Tariffs
Baseball
Natural Disasters
Donald Trump
Social Media
Trade War
Tennis
Trade
Taxes
Stock Markets
Artificial Intelligence
European Union
Published • loading... • Updated

Eli Lilly pays struggling Sangamo $18M upfront to tap gene therapy capsid

Summary by Endpoints News
Eli Lilly is licensing Sangamo Therapeutics’ AAV capsid for an undisclosed CNS disease target, and the $18 million upfront fee should give the beleaguered biotech a much-needed cash injection. The deal centers on Sangamo’s STAC ...
DisclaimerThis story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.

2 Articles

All
Left
Center
Right
Endpoints NewsEndpoints News

Eli Lilly pays struggling Sangamo $18M upfront to tap gene therapy capsid

Eli Lilly is licensing Sangamo Therapeutics’ AAV capsid for an undisclosed CNS disease target, and the $18 million upfront fee should give the beleaguered biotech a much-needed cash injection. The deal centers on Sangamo’s STAC ...

Read Full Article
PharmaphorumPharmaphorum

Lilly throws lifeline to Sangamo with $1.4bn licensing deal

A new $1.4 billion gene therapy alliance with Eli Lilly has come at an opportune time for Sangamo as its cash reserves start to dry up

Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • There is no tracked Bias information for the sources covering this story.
Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

Pharmaphorum broke the news in on Friday, April 4, 2025.
Sources are mostly out of (0)
Stories disproportionately reported by the Left or the Right

Similar News Topics

Eli Lilly

Eli Lilly

You have read out of your 5 free daily articles.

Join us as a member to unlock exclusive access to diverse content.

News
For You
SearchBlindspotLocal